Related Experiment Video
Updated: Sep 9, 2025
09:14
Pre-Chiasmatic, Single Injection of Autologous Blood to Induce Experimental Subarachnoid Hemorrhage in a Rat Model
Published on: June 18, 2021
2.5K
SAHRANG: Subarachnoid Hemorrhage Recovery and Galantamine: A Pilot Multicenter Randomized Placebo-Controlled Trial
Bosco Seong Kyu Yang1, Jude P J Savarraj1, Elena Moreno1
1Departent of Neurosurgery, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, USA.
Neurocritical Care
|August 28, 2025
Summary
Galantamine is safe and well-tolerated in subarachnoid hemorrhage (SAH) patients. This pilot study found no significant differences in adverse events or mortality between galantamine and placebo groups in SAH treatment.
Area of Science:
- Neuroscience
- Pharmacology
- Clinical Trials
Background:
- Subarachnoid hemorrhage (SAH) frequently leads to long-term neurological deficits.
- Peripheral inflammation exacerbates SAH outcomes.
- Galantamine demonstrates potential in reducing neuroinflammation and enhancing synaptic function.
Purpose of the Study:
- To evaluate the tolerability and safety of galantamine in patients with SAH.
- To investigate galantamine's potential to mitigate inflammation-mediated neuronal injury.
- To assess galantamine's impact on outcomes following SAH.
Main Methods:
- A prospective, multicenter, double-masked, randomized, placebo-controlled pilot study.
- Enrolled 60 adult patients with aneurysmal SAH (Fisher grade 3) within 72 hours of symptom onset.
- Patients received either galantamine (8mg or 12mg every 12h) or placebo for 90 days, initiated within 36 hours of aneurysm securing.
Main Results:
- No significant differences in tolerability or safety were observed between galantamine and placebo groups.
- The most common adverse event was bradycardia (37%); discontinuation rates due to adverse events were similar.
- Mortality rates at 90 days did not differ significantly between the galantamine and placebo groups.
Conclusions:
- Galantamine demonstrated comparable tolerability and safety to placebo in SAH patients.
- The study supports the use of galantamine in early and subacute stages of SAH.
- Further research may explore galantamine's efficacy in improving SAH outcomes.
